Medicine Matters: PRESERVED-HF: Support for dapagliflozin to improve HFpEF health status

November 2, 2021

Mikhail Kosiborod, MD, Vice President of Research at Saint Luke's Health System, cardiologist at Saint Luke's Mid America Heart Institute, and the principal investigator of PRESERVED-HF outlines the findings from the PRESERVED-HF trial, demonstrating that dapagliflozin improves symptoms and physical function in people with heart failure with preserved ejection fraction, and discusses the promise of SGLT2 inhibitors for meeting the treatment goals in this population. 

The findings of the PRESERVED-HF trial, which offers potential new hope for people struggling with heart failure with preserved ejection fraction (HFpEF), were published on October 28, 2021, in the journal Nature Medicine.

Listen to the full interview with Medicine Matters: PRESERVED-HF: Support for dapagliflozin to improve HFpEF health status.

Related Content

Saint Luke's Mid America Heart Institute
PRESERVED-HF trial findings on the substantial impact of dapagliflozin in individuals with heart failure with preserved ejection fraction (HFpEF) published in Nature Medicine
The findings of the PRESERVED-HF trial, offering potential new hope for people struggling with heart failure with preserved ejection fraction (HFpEF), are published in the journal, Nature Medicine.
<none>
TCTMD: PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF
Dapagliflozin eases symptoms and physical limitations among patients who have heart failure with preserved ejection fraction (HFpEF) within a relatively short time period.
<none>
MD edge: PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEF
The SGLT2 inhibitor dapagliflozin scored a clear win in a randomized, controlled trial with more than 300 U.S. patients with heart failure with preserved ejection fraction (HFpEF).